Previous 10 | Next 10 |
Verve Therapeutics press release ( NASDAQ: VERV ): Q2 GAAP EPS of -$0.84 misses by $0.20 . Cash, cash equivalents and marketable securities were $293.6 million as of June 30, 2022, as compared to $360.4 million as of December 31, 2021. For further details see: ...
Over $300 Million in Capital Added to Balance Sheet, Supporting an Operating Runway into Second Half of 2025 Patient Dosing Underway with Lead Candidate, VERVE-101, for Treatment of Heterozygous Familial Hypercholesterolemia; Regulatory Clearances in the United Kingdom and Unite...
Over the past few days, there have been some monster moves across a number of Russell 3,000 stocks. Taking a look at the Russell 3,000 members that had at least been cut in half from the time of the index’s high on January 3rd through the low on June 16th, followed by a rally o...
CAMBRIDGE, Mass., July 25, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the closing of its previously announced upsize...
Verve Therapeutics (NASDAQ: VERV) , a biotech company specializing in gene-editing therapies to treat cardiovascular disease, has seen its shares rise 44.9% so far this week, according to data from S&P Global Intelligence . The stock closed last Friday at $23.71 and opened o...
Gainers: 1Life Healthcare ONEM +67% . Tabula Rasa HealthCare ( TRHC ) +27% . Cano Health ( CANO ) +15% . Repligen ( RGEN ) +15% . Oak Street Health ( OSH ) +10% . Losers: LumiraDx LMDX -25% . Verve Therapeuti...
Stronghold Digital Mining ( SDIG ) -18% . LumiraDx ( LMDX ) -17% . Verve Therapeutics ( VERV ) -17% after pricing common stock offering . Applied Blockchain ( APLD ) -14% . Pagaya Technologies ( PGY ) -14% . Carnival Corp...
The shares of Verve Therapeutics ( NASDAQ: VERV ) continue to trade lower in the pre-market Thursday with a 16% decline after the gene-editing company priced its previously announced underwritten public offering of common stock. Per the terms, Verve ( VERV ) intend...
CAMBRIDGE, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pricing of its upsized underwritten public...
Vertex Pharmaceuticals ( NASDAQ: VRTX ) and Verve Therapeutics ( NASDAQ: VERV ) will collaborate on developing a gene editing program for a liver disease . Under the four-year arrangement, Verve ( VERV ) will be responsible for discovery, research and certa...
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
Verve Therapeutics Inc. Website:
2024-07-08 07:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its boar...
2024-06-15 11:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...